Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy
Ellen Gelpi,Raphael Reinecke,Carles Gaig,Alex Iranzo,Lidia Sabater,Laura Molina-Porcel,Iban Aldecoa,Verena Endmayr,Birgit Högl,Erich Schmutzhard,Werner Poewe,Bettina Pfausler,Mara Popovic,Janja Pretnar-Oblak,Frank Leypoldt,Jakob Matschke,Markus Glatzel,Elena Maria Erro,Ivonne Jerico,Maria Cristina Caballero,Maria Victoria Zelaya,Sara Mariotto,Anna Heidbreder,Ognian Kalev,Serge Weis,Stefan Macher,Evelyn Berger-Sieczkowski,Julia Ferrari,Christoph Reisinger,Nikolaus Klupp,Pentti Tienari,Osma Rautila,Marja Niemelä,Deniz Yilmazer-Hanke,Mar Guasp,Bas Bloem,Judith Van Gaalen,Benno Kusters,Maarten Titulaer,Nina L. Fransen,Joan Santamaria,Thimoty Dawson,Janice L. Holton,Helen Ling,Tamas Revesz,Liisa Myllykangas,Herbert Budka,Gabor G. Kovacs,Jan Lewerenz,Josep Dalmau,Francesc Graus,Inga Koneczny,Romana Höftberger
DOI: https://doi.org/10.1007/s00401-024-02805-y
IF: 15.887
2024-10-16
Acta Neuropathologica
Abstract:Anti-IgLON5 disease is a unique condition that bridges autoimmunity and neurodegeneration. Since its initial description 10 years ago, an increasing number of autopsies has led to the observation of a broader spectrum of neuropathologies underlying a particular constellation of clinical symptoms. In this study, we describe the neuropathological findings in 22 patients with anti-IgLON5 disease from 9 different European centers. In 15 patients (68%), we observed a hypothalamic and brainstem-predominant tauopathy of varying severity in which the original research neuropathological criteria were readily applicable. This pathology was observed in younger patients (median age at onset 61 years) with a long disease duration (median 9 years). In contrast, in 7 (32%) patients, the originally described brainstem tauopathy was nearly absent or only minimal in the form of delicate threads, despite mild-to-moderate neurodegenerative features, consistent clinical symptoms and the presence of anti-IgLON5 antibodies in CSF and serum. These patients were older at onset (median 79 years) and had shorter disease duration (median < 1 year). Overall, about one-third of the patients showed concomitant TDP-43 pathology within the regions affected by tau pathology and/or neurodegeneration. Based on these observations and in view of the spectrum of the tau burden in the core regions involved in the disease, we propose a simple staging system: stage 1 mild neurodegeneration without overt or only minimal tau pathology, stage 2 moderate neurodegeneration and mild/ moderate tauopathy and stage 3 prominent neurodegeneration and tau pathology. This staging intends to reflect a potential (age- and time-dependent) progression of tau pathology, supporting the current notion that tau accumulation is a secondary phenomenon related to the presence of anti-IgLON5 antibodies in the CNS. Finally, we adapt the original research criteria of the anti-IgLON5 disease-related tauopathy to include the spectrum of pathologies observed in this larger postmortem series.
pathology,neurosciences,clinical neurology